Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects
Table 5
Summary of changes in laboratory measurements during the study.
Measurements
Pre- to poststudy changes
Low-dose IQP-AE-103 (mean ± s.d.)
High-dose IQP-AE-10 (mean ± s.d.)
Placebo (mean ± s.d.)
value
Hemoglobin (mmol/l)
−0.08 ± 0.48
0.09 ± 0.63
−0.04 ± 0.75
NS
Hematocrit (l/l)
−0.003 ± 0.029
−0.003 ± 0.028
−0.001 ± 0.036
NS
Erythrocytes (Tpt/l)
0.01 ± 0.31
0.02 ± 0.34
−0.02 ± 0.38
NS
Thrombocytes (Gpt/l)
8.6 ± 40.5
2.3 ± 42.1
0.8 ± 56.7
NS
Leukocytes (Gpt/l)
0.08 ± 1.55
−0.33 ± 1.65
0.16 ± 1.63
NS
Mean cell volume (fl)
−0.5 ± 3.5
−1.2 ± 5.4
0.1 ± 3.8
NS
Mean corpuscular hemoglobin (fmol/Ery)
−0.021 ± 0.058
0.013 ± 0.082
0.001 ± 0.076
NS
Mean corpuscular hemoglobin concentration (mmol/l)